Compare HUN & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | AVDL |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2005 | 1996 |
| Metric | HUN | AVDL |
|---|---|---|
| Price | $10.04 | $21.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $10.23 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 5.8M | 2.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,780,000,000.00 | $248,517,000.00 |
| Revenue This Year | N/A | $65.47 |
| Revenue Next Year | $3.40 | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $7.30 | $6.38 |
| 52 Week High | $20.94 | $23.57 |
| Indicator | HUN | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 59.01 |
| Support Level | $9.81 | $21.32 |
| Resistance Level | $10.69 | $21.62 |
| Average True Range (ATR) | 0.49 | 0.34 |
| MACD | 0.15 | -0.31 |
| Stochastic Oscillator | 72.26 | 6.90 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.